Akcea Connect UK
Akcea Therapeutics UK
- Akcea Therapeutics US

About us
News
Rare diseases
For healthcare professionals
For patients & families

The information contained in this section of the site is intended for UK healthcare professionals only. Please confirm you are a healthcare professional to continue.

I confirm I am a UK healthcare professional

Continue
Go back

News

Tegsedi™▼ (inotersen) to be made available on the NHS in England for people with hATTR amyloidosis

Published date: 16/04/2019

AKCUK-071 | September 2020

Back to news listing

Recent Posts

WAYLIVRA▼® (volanesorsen), the first and only therapy for familial chylomicronaemia syndrome, an ultra-rare and life-threatening condition, to be available on the NHS in Scotland
Akcea celebrates third global Familial Chylomicronaemia Syndrome (FCS) awareness day
WAYLIVRA▼® (volanesorsen), the first and only therapy for FCS, an ultra-rare and life-threatening condition, to be available on the NHS in England
Akcea response to draft negative guidance from NICE for WAYLIVRA▼® (volanesorsen), the only therapy for FCS, a devastating and ultra-rare disease
Tegsedi®▼ (inotersen) to be made available on the NHS in Scotland for people with rare hATTR amyloidosis

Terms of use
Cookie policy
Privacy policy
Careers
Contact us

Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/ Adverse events should also be reported to Akcea Therapeutics UK Ltd:
Email: MedInfoUK@akceatx.com
Telephone: +44 (0) 330 159 0174

© 2020, all rights reserved.
AKC-056-002 | September 2020

Akcea Therapeutics UK Ltd,

Regus Building
Brooklands Business Park
Wellington Way
Weybridge
Surrey
KT13 0TT
UK

+44 (0)1932 871862
UKinfo@akceatx.com
MedInfoUK@akceatx.com